Application of stable silicic acid aqueous solution in preparation of product for treating skin superficial fungal infection and product

Abstract

The invention relates to application of a stable silicic acid aqueous solution in preparation of a product for treating skin superficial fungal infection and the product, and the mass concentration of the stable silicic acid aqueous solution is 0.5-2%. The product taking the stable silicic acid aqueous solution as an active ingredient can be used for treating skin superficial fungal infection or trichophyton rubrum infection, can resist trichophyton rubrum infection at the mass concentration of 0.5-2%, has the effect of resisting skin superficial fungal infection, and meanwhile, the stable silicic acid aqueous solution is low in raw material cost, environment-friendly, safe and suitable for industrial production. And an innovative direction is provided for treatment of skin superficial fungal infection and skin tinea.

Description

Technical Field

[0001] The invention relates to the technical field of biomedicine, and in particular to an application of a stable silicic acid aqueous solution in the preparation of a product for treating superficial fungal infections of the skin and a product thereof. Background Art

[0002] Trichophyton rubrum is a species of the genus Trichophyton. It is a human dermatophyte that causes common superficial fungal diseases of the skin, such as tinea manuum, tinea pedis, tinea capitis, etc.

[0003] Commonly used drugs for tinea dermatophyte include miconazole, econazole, ketoconazole, bifonconazole, terbinafine, naftifine, amorolfine, ciclopirox olamine, liranapthate, etc. For those with severe inflammation, compound econazole nitrate cream can be used, but it should not be used for too long to avoid adverse reactions. Currently, the main treatment drugs for this fungus are chemically synthesized antifungal drugs, but they have the following limitations:

[0004] The problem of drug resistance is prominent. With the widespread use of antifungal drugs, the resistance of Trichophyton rubrum to allylamine drugs such as terbinafine has increased significantly. In addition, although azole drugs (such as itraconazole and fluconazole) are effective against some drug-resistant bacteria, Trichophyton rubrum has predictable resistance to fluconazole, requiring combined use of drugs or the selection of new drugs such as voriconazole, which further increases the complexity of treatment.

[0005] Safety risks and side effects. Oral antifungal drugs have the risk of liver toxicity, requiring regular monitoring of liver function, and are contraindicated in patients with chronic liver disease or specific metabolic abnormalities. Although topical drugs have a higher local safety, they may cause skin irritation or allergic reactions, and some patients have poor compliance.

[0006] Based on the above problems, it is urgent to develop new drugs to resist superficial fungal infections of the skin for the treatment of tinea. Summary of the invention

[0007] The purpose of the present invention is to address the above-mentioned problems existing in drugs for superficial fungal infections of the skin and to propose an alternative drug, which utilizes a stable silicic acid aqueous solution to prepare a product for treating superficial fungal infections of the skin to obtain better therapeutic effects.

[0008] To achieve the above-mentioned object, the present invention provides an application of a stable silicic acid aqueous solution in the preparation of a product for treating superficial fungal infections of the skin, wherein the mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

[0009] Furthermore, the present invention provides an application of a stable silicic acid aqueous solution in the preparation of a product for treating Trichophyton rubrum infection, wherein the mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

[0010] Furthermore, the present invention provides an application of a stable silicic acid aqueous solution in the preparation of a product for treating tinea dermatophyte, wherein the mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

[0011] Preferably, when used for external application, the stable silicic acid aqueous solution is dispersed in an ointment base as an active ingredient.

[0012] Furthermore, the present invention provides a product for treating superficial fungal infections of the skin or for treating Trichophyton rubrum infections, wherein the active ingredient of the product is a stable silicic acid aqueous solution with a mass concentration of 0.5% to 2%, and the product is a medical device or a drug.

[0013] Based on the above technical solution, the advantages of the present invention are:

[0014] The stable silicic acid aqueous solution of the present invention is used as an active ingredient, and can resist Trichophyton rubrum infection at a mass concentration of 0.5% to 2%, has clinical application value in resisting pathogenic fungi, and has the effect of resisting superficial fungal infection of the skin. At the same time, the raw material cost of the stable silicic acid aqueous solution is low, and it is environmentally friendly and safe, and can be used as a substitute for traditional drugs with good therapeutic effects.

[0015] The present invention proposes to use a stable silicic acid aqueous solution as an alternative therapeutic agent, which destroys the fungal structure through physical and chemical effects, has a low risk of drug resistance, high biocompatibility and broad-spectrum antibacterial potential, and provides an innovative direction for the treatment of superficial fungal infections of the skin and psoriasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of this application. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0017] Figure 1 , A is a photo of the culture of mice infected with Trichophyton rubrum treated with the control group (untreated), miconazole, and metasilicic acid aqueous solution, and the bacterial load of Trichophyton rubrum in the infection site was evaluated;

[0018] Figure 1 , B is the evaluation results of the bacterial load of Trichophyton rubrum in the infected area of ​​mice infected with Trichophyton rubrum treated with the control group (untreated), miconazole, and metasilicic acid aqueous solution;

[0019] Figure 2 Phenotypic changes in mice infected with Trichophyton rubrum after treatment with the control group (untreated), miconazole, and metasilicic acid aqueous solution. DETAILED DESCRIPTION

[0020] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments.

[0021] The present invention provides an application of a stable silicic acid aqueous solution in preparing a product for treating superficial fungal infections of the skin, wherein the mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

[0022] It should be noted that the stable silicic acid aqueous solution in the present invention is a stable stable silicic acid aqueous solution, wherein the stable silicic acid aqueous solution refers to a solution in a stable state without polymerization, and its main components include monosilicic acid (H4SiO4), metasilicic acid (H2SiO3) and hydrogen silicate (HSiO3 - ), the mass concentration of 0.5% to 2% in the present invention means that the total concentration of the main components is 0.5% to 2%.

[0023] In order to illustrate the application effect of the stable silicic acid aqueous solution in the preparation of a product for treating superficial fungal infection of the skin, this example takes BALB / c Nude mice as the infection object to simulate the human superficial fungal infection model as an example for explanation:

[0024] (1) Model establishment

[0025] Superficial fungal infection model of the skin: BALB / c Nude mice were used as the infection subjects, and a 4 mm mouse skin punch was used to punch holes on the mouse skin surface to simulate combat injuries (see the specific location for details). Figure 2 The mouse image is shown in the figure). Trichophyton rubrum (one of the most common superficial fungi on the skin) was selected to infect the skin punch area. The infection dose of Trichophyton rubrum was 10 μL with a concentration of 10 9 cells / mL of spore suspension is inoculated into the wound to infect the host, and treatment begins after colonization.

[0026] (2) Experimental groups and treatment plans

[0027] Three groups were set up for each fungal infection experiment: control group, drug treatment group and metasilicic acid aqueous solution treatment group. The control group used sterile water, the drug group used antifungal drug miconazole with a concentration of 100μg / mL, and the metasilicic acid aqueous solution group used a stable silicic acid aqueous solution with a mass concentration of 1%. A 15 mL nozzle was used to spray the infected area of ​​the mice 10 times a day, twice a day, for 7 consecutive days, and the treatment effect was observed and the bacterial load and other phenotypes were measured to conduct a comprehensive evaluation of the antifungal effect.

[0028] (3) Observation indicators

[0029] a. Observe the wound changes in the infected area of ​​the mice after treatment and monitor the diet and mental state of the mice;

[0030] b. The infected area of ​​the mouse was dissected and removed, and after homogenization and filtration, the bacterial load was tested and statistically analyzed.

[0031] (4) Effect of metasilicic acid aqueous solution on the removal of Trichophyton rubrum infection

[0032] Compared with the untreated control group, mice infected with metasilicic acid solution were sprayed 10 times a day with a 15 mL spray head on the infected area of ​​the mice, twice a day (sprayed once every 8 hours), for 7 consecutive days. The bacterial load of Trichophyton rubrum in the infected area was significantly reduced (detected 7 days after treatment) (see Figure 1 A, B); At the same time, the drug treatment group took miconazole at a concentration of 100 μg / mL, and sprayed the infected area of ​​the mice 10 times a day with a 15 mL nozzle, twice a day. Compared with the untreated control group infected mice, the fungal load of Trichophyton rubrum in the infected area was significantly reduced (see Figure 1 A, B).

[0033] In addition, compared with the untreated control group infected mice, the infection symptoms of mice treated with metasilicic acid aqueous solution for 7 days were significantly suppressed and showed an improvement trend (see Figure 2 ); At the same time, after 7 days of treatment with 100μg / mL miconazole, the infection symptoms of the infected part of the mice in the drug treatment group were significantly suppressed compared with the untreated control group infected mice, showing a trend of improvement (see Figure 2 ).

[0034] (5) Conclusion

[0035] A stable silicic acid aqueous solution was used to treat mice infected with Trichophyton rubrum. The mice were sprayed 10 times a day with a 15 mL spray nozzle on the infected area, twice a day (with an interval of 8 hours between the two times). After one week of treatment, the fungal load in the infected area of ​​the mice infected with Trichophyton rubrum was significantly decreased, and the infection symptoms in the infected area were significantly suppressed, showing a trend of improvement.

[0036] Since Trichophyton rubrum infection is often a typical manifestation of superficial fungal infection of the skin, the stable silicic acid aqueous solution of the present invention can also be used in the preparation of products for treating superficial fungal infection of the skin, wherein the mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%. Furthermore, since the stable silicic acid aqueous solution of the present invention can resist Trichophyton rubrum infection, the stable silicic acid aqueous solution of the present invention can be used in the preparation of products for treating dermatophyte, wherein the mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

[0037] When used for external application, the stable silicic acid aqueous solution is dispersed in an ointment matrix as an active ingredient to obtain a more suitable use mode.

[0038] Furthermore, the present invention provides a product for treating superficial fungal infections of the skin or for treating Trichophyton rubrum infections, wherein the active ingredient of the product is a stable silicic acid aqueous solution with a mass concentration of 0.5% to 2%, and the product is a medical device or a drug.

[0039] The stable silicic acid aqueous solution of the present invention is used as an active ingredient, and can resist infection with Trichophyton rubrum at a mass concentration of 0.5% to 2%, has clinical application value in resisting pathogenic fungi, and has the effect of resisting superficial fungal infection of the skin. At the same time, the raw material cost of the stable silicic acid aqueous solution is low, and it is environmentally friendly and safe, and can be used as a substitute for the traditional drug miconazole with good therapeutic effect.

[0040] The present invention proposes to use a stable silicic acid aqueous solution as an alternative therapeutic agent, which destroys the fungal structure through physical and chemical effects, has a low risk of drug resistance, high biocompatibility and broad-spectrum antibacterial potential, and provides an innovative direction for the treatment of superficial fungal infections of the skin and psoriasis.

[0041] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, ordinary technicians in the field should understand that the specific implementation methods of the present invention can still be modified or some technical features can be replaced by equivalents without departing from the spirit of the technical solution of the present invention, which should be included in the scope of the technical solution for protection of the present invention.

Claims

1. Application of a stable silicic acid aqueous solution in the preparation of a product for treating superficial fungal infections of the skin, wherein: The mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

2. Application of a stable silicic acid aqueous solution in the preparation of a product for treating Trichophyton rubrum infection, wherein: The mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

3. Application of a stable silicic acid aqueous solution in the preparation of a product for treating tinea dermatitis, wherein: The mass concentration of the stable silicic acid aqueous solution is 0.5% to 2%.

4. The use according to claim 1, characterized in that: When used for external application, the stable silicic acid aqueous solution is dispersed in an ointment base as an active ingredient.

5. The use according to claim 2, characterized in that: When used for external application, the stable silicic acid aqueous solution is dispersed in an ointment base as an active ingredient.

6. The use according to claim 3, characterized in that: When used for external application, the stable silicic acid aqueous solution is dispersed in an ointment base as an active ingredient.

7. A product for treating superficial fungal infections of the skin or for treating Trichophyton rubrum infections, characterized in that: The active ingredient of the product is a stable silicic acid aqueous solution with a mass concentration of 0.5% to 2%, and the product is a medical device or a drug.

Images